1-3 of 3
Wenbin Qian, MD PhD
Close
Sort by
Journal Articles

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

Hui-qiang Huang, MD PhD, Rong Tao, MD PhD, Liqun Zou, Hong Cen, MD PhD, Ye Guo, MD PhD, Yunhong Huang, MD PhD, Wenbin Qian, MD PhD, Liling Zhang, MD PhD, Hui Zhou, MD PhD, Yu Yang, MD PhD, Haiyan Yang, Dan Zhu, Teng Fang, PhD, Hangjun Dai, Yueling Wang, Jianxin Yang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2833.
https://doi.org/10.1182/blood-2019-121865
Published: 2019
Journal Articles

Shikonin Overcomes Drug Resistance and Induces Necroptosis By Regulating the Mir-92a-1-5p/Mlkl Axis in Chronic Myeloid Leukemia Cells

Xianbo Huang, MD PhD, Jie Jin, MD PhD, Wenbin Qian, MD PhD, Xiujin Ye, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1633.
https://doi.org/10.1182/blood-2019-125600
Published: 2019
Journal Articles

Clinical Characteristics of T-Cell Lymphoma Associated Hemophagocytic Syndrome: Comparison of T-Cell Lymphoma with and without Hemophagocytic Syndrome.

Hongyan Tong, MD, PhD, Yanling Ren, MD, Feng Xiao, MD, Wenyuan Mai, MD, PhD, Haitao Meng, MD, PhD, Wenbin Qian, MD, PhD, Jie Jin, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3576.
https://doi.org/10.1182/blood.V110.11.3576.3576
Published: 2007